These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 19179977

  • 1. Prognostic relevance of cyclin E expression in operable breast cancer.
    Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK, Kordek R.
    Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
    [Abstract] [Full Text] [Related]

  • 2. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining.
    Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Jesionek-Kupnicka D, Pasz-Walczak G, Watala C, Kordek R.
    Jpn J Clin Oncol; 2006 Mar; 36(3):142-9. PubMed ID: 16520356
    [Abstract] [Full Text] [Related]

  • 3. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Mar; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 4. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation.
    Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R.
    J Exp Clin Cancer Res; 2006 Mar; 25(1):59-64. PubMed ID: 16761619
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [Abstract] [Full Text] [Related]

  • 8. Cyclin E and survival in patients with breast cancer.
    Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS.
    N Engl J Med; 2002 Nov 14; 347(20):1566-75. PubMed ID: 12432043
    [Abstract] [Full Text] [Related]

  • 9. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P, Stighall M, Jirström K, Rydén L, Fernö M, Nordenskjöld B, Landberg G.
    J Clin Pathol; 2008 Feb 14; 61(2):184-91. PubMed ID: 17483245
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
    Peters MG, Vidal Mdel C, Giménez L, Mauro L, Armanasco E, Cresta C, Bal de Kier Joffé E, Puricelli L.
    Oncol Rep; 2004 Nov 14; 12(5):1143-50. PubMed ID: 15492807
    [Abstract] [Full Text] [Related]

  • 11. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Mar 15; 14(6):1767-74. PubMed ID: 18347178
    [Abstract] [Full Text] [Related]

  • 12. Cell cycle dysregulation influences survival in high risk breast cancer patients.
    Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C.
    Cancer Invest; 2008 Aug 15; 26(7):734-40. PubMed ID: 18665474
    [Abstract] [Full Text] [Related]

  • 13. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG.
    Oncogene; 2003 Jul 31; 22(31):4898-904. PubMed ID: 12894232
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic value of cyclin E and its relation to blood vessel invasion in rectal cancer].
    Zhou YJ, Wan FL, Yao LH, Feng LY.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Mar 31; 11(2):167-71. PubMed ID: 18344087
    [Abstract] [Full Text] [Related]

  • 15. Relationship of P-cadherin expression to basal phenotype of breast carcinoma.
    Potemski P, Kusińska R, Kubiak R, Piekarski JH, Płuciennik E, Bednarek AK, Kordek R.
    Pol J Pathol; 2007 Mar 31; 58(3):183-8. PubMed ID: 18074863
    [Abstract] [Full Text] [Related]

  • 16. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY.
    Jpn J Clin Oncol; 2007 Sep 31; 37(9):708-14. PubMed ID: 17940078
    [Abstract] [Full Text] [Related]

  • 17. A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes.
    Tenderenda M.
    J Exp Clin Cancer Res; 2005 Sep 31; 24(3):405-14. PubMed ID: 16270527
    [Abstract] [Full Text] [Related]

  • 18. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T.
    J Surg Res; 2008 May 01; 146(1):104-9. PubMed ID: 17663001
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications.
    Donnellan R, Kleinschmidt I, Chetty R.
    Hum Pathol; 2001 Jan 01; 32(1):89-94. PubMed ID: 11172300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.